Figure 2From: Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of Pioglitazone, Metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB studyMMP-9 and Secondary Efficacy: Mean Difference to Baseline after 6 months.Back to article page